Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
November 24, 2025
Clinical performance of scalable automated p-tau 217 multi-analyte algorithmic blood test with reduced intermediate zone using multiplexed digital immunoassay
David H Wilson, Karen Copeland, Mike Miller, et al.
Cancer
|
June 8, 2012
A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion
Georgia M Beasley, Ketan Sharma, Joyce Wong, et al.
Frontiers in Neurology
|
July 25, 2025
Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
David Wilson, Meenakshi Khare, Gallen Triana-Baltzer, et al.
Sports Medicine (Auckland, N.Z.)
|
October 3, 2023
Technology Innovation and Guardrails in Elite Sport: The Future is Now
Fergus Guppy, Borja Muniz-Pardos, Konstantinos Angeloudis, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 11, 2011
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase
Robert Gomez, Samson Jolly, Theresa Williams, et al.
Journal of Medicinal Chemistry
|
October 12, 2011
Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase
Robert Gomez, Samson J Jolly, Theresa Williams, et al.
Journal of Medicinal Chemistry
|
October 2, 2008
Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses
Thomas J Tucker, John T Sisko, Robert M Tynebor, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 9, 2008
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations
Thomas J Tucker, Sandeep Saggar, John T Sisko, et al.
Journal of Medicinal Chemistry
|
November 4, 2009
Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses
Dai-Shi Su, John J Lim, Elizabeth Tinney, et al.
Sports Medicine - Open
|
August 10, 2020
Collateral Health Issues Derived from the Covid-19 Pandemic
Borja Muniz-Pardos, Jonathan Shurlock, Andre Debruyne, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
November 24, 2025
Clinical performance of scalable automated p-tau 217 multi-analyte algorithmic blood test with reduced intermediate zone using multiplexed digital immunoassay
David H Wilson, Karen Copeland, Mike Miller, et al.
Cancer
|
June 8, 2012
A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion
Georgia M Beasley, Ketan Sharma, Joyce Wong, et al.
Frontiers in Neurology
|
July 25, 2025
Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
David Wilson, Meenakshi Khare, Gallen Triana-Baltzer, et al.
Sports Medicine (Auckland, N.Z.)
|
October 3, 2023
Technology Innovation and Guardrails in Elite Sport: The Future is Now
Fergus Guppy, Borja Muniz-Pardos, Konstantinos Angeloudis, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 11, 2011
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase
Robert Gomez, Samson Jolly, Theresa Williams, et al.
Journal of Medicinal Chemistry
|
October 12, 2011
Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase
Robert Gomez, Samson J Jolly, Theresa Williams, et al.
Journal of Medicinal Chemistry
|
October 2, 2008
Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses
Thomas J Tucker, John T Sisko, Robert M Tynebor, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 9, 2008
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations
Thomas J Tucker, Sandeep Saggar, John T Sisko, et al.
Journal of Medicinal Chemistry
|
November 4, 2009
Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses
Dai-Shi Su, John J Lim, Elizabeth Tinney, et al.
Sports Medicine - Open
|
August 10, 2020
Collateral Health Issues Derived from the Covid-19 Pandemic
Borja Muniz-Pardos, Jonathan Shurlock, Andre Debruyne, et al.
Page
of 4